Your session is about to expire
← Back to Search
Unknown
TAK-861 for Narcolepsy
Phase 2
Waitlist Available
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 16 weeks
Summary
This trial is testing a new drug called TAK-861 to see if it can help people with narcolepsy feel less sleepy during the day and have fewer episodes of sudden muscle weakness. The study will include about 100 participants from different parts of the world.
Who is the study for?
Adults aged 18-70 with narcolepsy type 1 confirmed by sleep tests, a BMI of 18-40 kg/m^2, and specific genetic markers or low levels of the brain hormone orexin. Excluded are those with significant medical conditions like heart disease, liver or thyroid issues, history of cancer within five years (except certain skin cancers), head trauma, seizures, stroke risks, infectious diseases like hepatitis B/C or HIV, poor kidney function or high liver enzyme levels.
What is being tested?
The study is testing TAK-861 to see if it improves daytime sleepiness and cataplexy in people with narcolepsy. Participants will randomly receive either TAK-861 or a placebo for up to 12 weeks across various regions globally. Afterward, they may join an extension study where everyone gets TAK-861.
What are the potential side effects?
While the trial doesn't explicitly list side effects for TAK-861 since it's under investigation, common side effects for narcolepsy medications can include headache, nausea, dizziness and irritability. The exact side effects will be monitored throughout the trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to approximately 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 16 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change from Baseline to Week 8 in Mean Sleep Latency from the Maintenance of Wakefulness Test (MWT)
Secondary study objectives
Change from Baseline to Week 8 in Epworth Sleepiness Scale (ESS) Total Score
Occurrence of at Least One Related Treatment-emergent Adverse Event (TEAE)
Trial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: TAK-861 Dose 4Experimental Treatment1 Intervention
Participants will receive TAK-861 dose 4, orally, from Day 1 up to Weeks 8 or 12.
Group II: TAK-861 Dose 3Experimental Treatment1 Intervention
Participants will receive TAK-861 dose 3, orally, from Day 1 up to Weeks 8 or 12.
Group III: TAK-861 Dose 2Experimental Treatment1 Intervention
Participants will receive TAK-861 dose 2, orally, from Day 1 up to Weeks 8 or 12.
Group IV: TAK-861 Dose 1Experimental Treatment1 Intervention
Participants will receive TAK-861 dose 1, orally, from Day 1 up to Weeks 8 or 12.
Group V: PlaceboPlacebo Group1 Intervention
Participants will receive TAK-861 matching placebo tablets, orally, from Day 1 up to Weeks 8 or 12.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TAK-861
2023
Completed Phase 2
~190
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Narcolepsy often target the central nervous system to alleviate symptoms such as excessive daytime sleepiness and cataplexy. Stimulants like modafinil and amphetamines increase wakefulness by enhancing dopamine and norepinephrine activity.
Sodium oxybate, another treatment, improves nighttime sleep and reduces cataplexy by acting on GABA receptors. Orexin receptor agonists, such as TAK-861, aim to mimic the action of orexin, a neuropeptide that regulates wakefulness and REM sleep.
These treatments are crucial for Narcolepsy patients as they address the underlying neurochemical imbalances, thereby improving daily functioning and quality of life.
[Roles of orexin and effects of orexin receptor antagonists].The effect of insomnia definitions, terminology, and classifications on clinical practice.
[Roles of orexin and effects of orexin receptor antagonists].The effect of insomnia definitions, terminology, and classifications on clinical practice.
Find a Location
Who is running the clinical trial?
TakedaLead Sponsor
1,240 Previous Clinical Trials
4,149,359 Total Patients Enrolled
10 Trials studying Narcolepsy
1,313 Patients Enrolled for Narcolepsy
Study DirectorStudy DirectorTakeda
1,290 Previous Clinical Trials
502,400 Total Patients Enrolled
7 Trials studying Narcolepsy
1,114 Patients Enrolled for Narcolepsy
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a significant heart condition such as heart disease, heart attack history, severe chest pain, abnormal heart rhythm, or heart failure.You have a medical condition other than narcolepsy with cataplexy that causes excessive daytime sleepiness.You had cancer in the past 5 years, except for certain types like early-stage skin cancers.You have tested positive for hepatitis B, hepatitis C, or HIV.Your kidneys are not working well, and your creatinine clearance is less than 50 mL/minute.Your liver enzymes (ALT or AST) are more than 1.5 times the normal level.Your body mass index (BMI) is between 18 and 40.You have been diagnosed with narcolepsy type 1 within the last 10 years using specific sleep tests.You have a specific genetic marker or low levels of a substance in your spinal fluid related to a sleep disorder.You or someone in your family has a history of seizures, except for one seizure caused by a fever when you were a child.You have certain mental health conditions, including unstable psychiatric disorder, history of manic or hypomanic episodes, schizophrenia, major depression with psychotic features, substance use disorder, or have been recently depressed.
Research Study Groups:
This trial has the following groups:- Group 1: TAK-861 Dose 1
- Group 2: TAK-861 Dose 2
- Group 3: TAK-861 Dose 3
- Group 4: TAK-861 Dose 4
- Group 5: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.